Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Gabriel who wrote (112809)	8/29/2000 11:24:10 PM
From: Frederick Langford	Respond to of 120523

BOOKHAM TECHNOLOGY: Bookham Technology introduces multi-channel DWDM integrated Optical Channel Monitor AUG 29, 2000, M2 Communications - Denver -- Bookham Technology today introduces its new Optical Channel Monitor (OCM) with a live demonstration at the National Fiber Optic Engineers Conference (NFOEC) in Denver. The OCM is a multi-channel dense wavelength division multiplexing (DWDM) integrated optical component designed for use in systems with up to 40 channels. In July, Bookham Technology announced that it is supplying the OCM product to a major WDM customer. "The OCM is a key product in our DWDM portfolio which clearly demonstrates the multi-functional integration capabilities of ASOC," said David Gahan, director of DWDM products, Bookham Technology. The OCM is the first example of an arrayed waveguide grating (AWG) based product with added functionality - optical detection. It uses a series of integrated photodetectors that sample each channel simultaneously. This allows measurement of power to be made in real time, enabling channels in long-haul point-to-point or metro ring to be balanced by banks of electronic variable optical attenuators (EVOA). Since the OCM can monitor all DWDM channels simultaneously it can be used as an effective optical protection device, as any drop in signal strength can be detected, or simply as a monitor to allow network operators to keep track of which channels are in operation. The output of the OCM is in the form of electrical signals that can be fed back into the system for control purposes. Bookham Technology`s ASOC uses well-understood silicon manufacturing processes to produce integrated optical components. Their solid-state nature confers high reliability, whilst the manufacturing process lends itself to automation and volume production. ASOC also allows the integration of several optical functions on a single device as system architectures progress and the need for miniaturisation increases. Bookham Technology (LSE: BHM: Nasdaq: BKHM) designs, manufactures and markets optical components which allow communications networks to be constructed efficiently to meet the growing demands of Internet traffic. Using patented silicon-based ASOC technology, the company's products generate, detect, route and control light signals in the next-generation optical communication networks. The company, which is quoted on Nasdaq and the London Stock Exchange, is headquartered in the UK and has offices in the US, France and Japan. More information on Bookham Technology is available at bookham.com -0- (C)1994-2000 M2 COMMUNICATIONS LTDCONTACT: Rachel Woodford, Bookham Technology Tel: +44 (0)12 3582 7200 e-mail: rachel.woodford@bookham.com Rhonda Barnat, Abernathy Macgregor Tel: +1 212 371 5999 e-mail: rb@abmac.com Andy Gothard/Jo Thompson, EML Tel: +44 (0)20 8408 8000 e-mail: andyg@eml.com ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at presswire.net on the world wide web. Inquiries to info@m2.com)).

To: Gabriel who wrote (112809)	8/29/2000 11:43:16 PM
From: SMALL FRY	Read Replies (2) \| Respond to of 120523

I remember CAMP. Jenna was pounding the table on this one almost a year ago when it was 11 or 12... I had about 500 sh, rode it to about 18 or 19 I think... then I forgot to set stops and I didn't catch it until it was down to about 15... <g> Looks like its doing very well now... chart looks like it recovered well. You think I should watch it again? I think it was one of your posts that got me looking at FNSR's chart too... then it popped and I was at the terminal, first in line. <g> Maybe I'll camp on CAMP again. <VBG> SF

To: Gabriel who wrote (112809)	8/30/2000 1:54:09 AM
From: Susan G	Read Replies (1) \| Respond to of 120523

Get Ready for a Biotech Frenzy By Lissa Morgenthaler Special to TheStreet.com Originally posted at 4:21 PM ET 8/28/00 on RealMoney.com What a rush! The RealMoney gang said that because I did a good job running my mutual fund for the first half of this year, I could come play with them during summer vacation. Now that biotech has more than 420 public companies and a market cap north of $400 billion, they think it's not just for girly men anymore. RealMoney.com columnist Gabe Hoffman and TSC staff reporter Dane Hamilton are obviously studs; you'd think the other guys would have figured it out sooner. (The fact that biotech is up 81% year to date probably got their attention.) So here I am --- just in time for the unofficial start of the autumn biotech frenzy. And did you see the kickoff last week? The trigger was the issuance of funding guidelines for stem-cell research by the National Institute of Health. And the starting gun was fired by President Clinton when he commented publicly that stem-cell research has enormous potential for fighting disease. There's such a nice symmetry to all this. Clinton tanked the biotech sector on March 14, plus he and Al Gore have been kicking health care companies on a semimonthly basis ever since. (Al gave biotech a solid hit just recently after his knock on pharmaceutical companies during the Democrat Convention's closing night.) But then Clinton sanctioned federal funding of research on stem cells, including those derived from frozen embryos that are to be discarded. This time when he kicked biotech he happened to be facing the goalposts. Up it went. And it was good! (The biotech indices haven't been this high in more than a month and they'll presumably break through their highs of mid-July before the end of this move.) All this didn't happen in a vacuum, of course. Some of the U.K. biotech companies clarified their stance on stem cells two weeks ago. (Upshot: They're willing to clone human organs but not humans.) Meanwhile, the institutions have been gorging on biotech IPO candy this summer --- and now they've gotten back to the main course. Robertson Stephens' Mike King focused their minds by running a very select visit to Millennium Pharmaceutical (MLNM:Nasdaq - news) last week (at which Millennium wouldn't allow more than 20 people, so clients were fighting to get on the tour.) Then King initiated coverage of Human Genome Sciences (HGSI:Nasdaq - news) with a buy rating -- which was the first stock to really move in biotech's big run late last week, and closed up about $20. Technically, this was all very timely. The AMEX and Nasdaq Biotech Indices have been hanging around their 50-day moving averages, which formed a little plateau two weeks ago. When we see that, no matter how bearish we are, we figure the stocks are headed up because they simply refuse to go down. (GBS, what do you see when you look at those flat spots in the Biotechnology Index (BTK.X:INDEX - news) and the Combined Biotech Index (IXBTX:INDEX - news)?) Then we heard the Investors Intelligence sentiment numbers last Wednesday, which are a measure of newsletter writers' attitudes toward the stock market. Having been a writer for a newsletter, I can't believe anybody pays attention to newsletter sentiment, let alone quantifying it. But Dame Meisler was dead right in her column last week: 43.8% bulls is a startlingly low number and suggested some sort of short-term bottom. Add in thin summer trading, which provides ripe conditions for someone with enough cash to yank biotech in one direction or another. We noticed this when we bought some Celera (CRA:NYSE - news) for our mutual fund and couldn't do it without moving the stock big time. The traders we deal with are going nuts trying to get stuff done. So along comes the stem-cell announcement and bang! We were grateful for a variety of reasons, including the fact that we have buys on both Geron (GERN:Nasdaq - news) and Nexell Therapeutics (NEXL:Nasdaq - news) in our newsletters. At the moment, we think they have the strongest intellectual property portfolio in the stem cell arena, though there will be lots of players. Geron has rights to, among other things, the Scottish nuclear transfer technology that created Dolly the sheep (although Geron shares many of those rights with PPL Therapeutics in the U.K.). And Nexell's goal is to industrialize the process of gathering, manipulating, and growing up stem cells. (If you remember the two little French boys from last May who had gene therapy and were still doing well 10 months later, that experiment used Nexell's ISOLEX system.) CNBC focused on a couple of other companies last week: Aastrom Biosciences (ASTM:Nasdaq - news) and StemCells (STEM:Nasdaq - news). Aastrom and Nexell are fairly direct competitors. I liked Aastrom very much when Cowen took them public several years ago, but it worries me that neither Geron nor Nexell have felt the need to cross-license with Aastrom. And StemCells is a homeboy for me (based in Sunnyvale, Calif.) This company is the old CytoTherapeutics, which was based in Rhode Island and focused on diseases of the central nervous system. There are several other companies in the field that didn't get mentioned, including Incara (INCR:Nasdaq - news) which has some technology related to liver progenitor cells. But altogether the kickoff of the fall biotech frenzy was great fun. It should run pretty smoothly until the BioCentury/Carson Group conference on Sept. 7. That's sort of the first financial confab of the season and it was the venue where Genentech and Idec Pharmaceuticals (IDPH:Nasdaq - news) last year let it be known that sales of their monoclonal antibody Rituxan were light. (That revelation started a biotech sag that lasted until nearly November.) And as the lockups come off the 50+ recent biotech IPOs and secondaries (thank you Ben Holmes), we figure there'll be at least $10 billion worth of overhang coming into the market. So there'll be the usual element of picking your way through biotech land mines this fall. But with Celera due to publish its semiannotated sequence of the human genome (probably next month) and a ton of clinical data due to report, we are looking forward to this fall with relish. (Or is that only in baseball?)